United States Human Papilloma Virus Testing Market Report by Application, Product, Technology, End Use, States and Company Analysis, 2026-2034

United States Human Papilloma Virus Testing Market: Future Outlook, Growth Trends & Forecast (2026–2034)

United States Human Papilloma Virus Testing Market is expected to reach US$ 1,107.19 Million by 2034 from US$ 499.79 Million in 2025, with a CAGR of 9.24% from 2026 to 2034. Growing emphasis on cervical cancer prevention, expanded HPV screening, self-collection options, improved molecular diagnostics, and automated laboratory workflows is accelerating HPV testing adoption in the United States. Healthcare providers increasingly favor accessible, sensitive, and efficient testing approaches for earlier risk identification.

United States Human Papilloma Virus Testing Industry Landscape

Human Papillomavirus (HPV) testing is a molecular diagnostic procedure used to identify high-risk HPV types associated with cervical cancer and other HPV-related diseases. Tests generally detect viral DNA or RNA from cervical or vaginal specimens using nucleic-acid amplification technologies. HPV testing can support primary cervical cancer screening, co-testing with cytology, and follow-up of abnormal cervical findings. Newer approaches are also expanding access through self-collected vaginal specimens, allowing eligible individuals to collect samples in healthcare settings or other approved environments. Testing platforms may incorporate automated specimen processing, molecular amplification, genotype identification, and laboratory information systems, helping clinicians assess risk and determine appropriate follow-up according to established screening guidelines.

The United States HPV testing market is being propelled by increasing emphasis on accessible cervical cancer prevention and patient-centered screening. Healthcare providers are adopting molecular HPV testing, self-collection options, automated laboratory workflows, and improved diagnostic assays to simplify screening and strengthen early risk identification. Self-collected vaginal specimens can offer greater convenience for eligible individuals who may face barriers to traditional clinician-collected testing. At the same time, diagnostic companies are expanding partnerships and developing innovative testing platforms that integrate specimen collection with efficient laboratory processing. Growing awareness of HPV-related cancer risks and greater integration of molecular diagnostics into preventive healthcare are further encouraging healthcare organizations to modernize screening pathways and improve patient participation.

Recent Breakthroughs Shaping the United States Human Papilloma Virus Testing Industry

• In April 2025, Quest Diagnostics announced an initiative to broaden access to HPV screening for women at risk of cervical cancer. The program allows physicians to offer eligible patients the option of self-collecting HPV specimens in clinical and other healthcare settings. Quest also planned to extend physician-ordered self-collection services across its approximately 2,000 patient service centers nationwide. The initiative builds on Quest’s earlier self-collection services for vaginitis and other genital tract infections. The HPV offering uses Roche’s FDA-cleared self-collection solution, which is designed for use with the cobas HPV test and provides a convenient and discreet approach to specimen collection while maintaining clinically appropriate testing.
• In May 2024, Roche received FDA clearance for its HPV self-collection solution in the United States, representing an important development in expanding cervical cancer screening access. The solution enables eligible patients to collect their own vaginal specimens in a healthcare setting for HPV testing, supporting earlier identification of high-risk HPV infections and facilitating appropriate clinical follow-up. The development reflects broader efforts to make cervical cancer screening more accessible and patient-centered while supporting timely detection and prevention.

Major Growth Drivers Shaping the Future of United States Human Papilloma Virus Testing Sector

1. Self-Collection Creates More Accessible Screening Pathways

Self-collection is reshaping the U.S. HPV testing landscape by offering an additional pathway for individuals who may experience inconvenience, discomfort, scheduling difficulties, or other barriers associated with traditional clinician-collected cervical screening. The approach can make HPV testing more convenient while allowing laboratories to maintain molecular testing workflows. Diagnostic companies are developing collection systems designed to simplify specimen acquisition, transportation, processing, and reporting.

In July 2025, BD submitted an FDA application for a new at-home HPV testing solution, featuring a self-collection swab and laboratory robotics designed to process specimens and identify high-risk HPV strains. The development demonstrates how testing companies are connecting molecular diagnostics with decentralized screening models. As regulatory pathways and clinical implementation continue evolving, self-collection can support broader participation in preventive cervical-health programs.

2. Molecular Assay Innovation Strengthens Cervical Cancer Screening

Advances in molecular diagnostics are improving the ability of laboratories to detect clinically relevant high-risk HPV infections and integrate testing into sophisticated screening workflows. Modern assays can identify multiple high-risk HPV types using DNA- or RNA-based technologies, while automated instruments can improve laboratory throughput and standardization. These capabilities are supporting greater use of HPV testing for primary screening, triage, and follow-up.

In February 2026, the FDA approved updated indications for the Aptima HPV Assay, including primary cervical cancer screening, alongside existing applications for ASC-US triage and co-testing. The development highlights continued evolution in molecular HPV diagnostics and reinforces the role of validated laboratory assays in preventive healthcare. As providers increasingly emphasize risk-based screening, assay performance, workflow compatibility, and clinically meaningful HPV detection will remain important market considerations.

3. Expanded HPV Detection Supports More Comprehensive Screening

The development of broader HPV detection capabilities is encouraging laboratories and healthcare providers to consider increasingly comprehensive molecular screening strategies. Modern HPV assays can identify multiple high-risk viral types, while advances in genotyping can provide additional information relevant to patient-risk assessment and clinical follow-up. These technologies are particularly valuable as healthcare systems continue moving toward molecular-first approaches for cervical cancer prevention.

In November 2025, Molecular Designs launched the HPV Simplicity Panel, a multiplex PCR-based research-use-only panel designed to identify 14 high-risk HPV types. Although intended for research rather than routine clinical diagnosis, the launch illustrates continuing innovation in multiplex HPV detection. Together with improvements in automated instruments, specimen processing, and molecular workflows, broader detection technologies are expanding the diagnostic possibilities surrounding HPV research and screening.

Critical Challenges Facing the United States Human Papilloma Virus Testing Industry

1. Screening Access, Participation, and Patient Follow-Up

Although HPV testing is increasingly accessible, ensuring consistent participation across different populations remains an important challenge for the U.S. market. Screening can be affected by healthcare access, appointment availability, geographic barriers, patient discomfort, awareness, socioeconomic circumstances, and differences in engagement with preventive healthcare. Expanding self-collection may address some of these obstacles, but implementation requires appropriate patient education, clinician guidance, laboratory coordination, and follow-up pathways. A positive HPV result does not by itself represent cancer and may require additional clinical evaluation according to screening guidelines. Consequently, healthcare systems must ensure that increased testing access is matched by effective communication, appropriate triage, diagnostic follow-up, and treatment pathways. Building integrated screening programs that connect testing with timely clinical management will remain essential for translating advances in HPV diagnostics into meaningful cervical-cancer prevention.

2. Regulatory, Laboratory, and Implementation Complexity

HPV testing requires validated assays, appropriate specimen collection, quality-controlled laboratory processes, trained personnel, and compliance with regulatory and clinical requirements. As new technologies introduce self-collected specimens, automated workflows, expanded genotyping, and new testing environments, laboratories and healthcare organizations must ensure that each component operates within approved indications and established clinical pathways. Regulatory decisions can also influence how rapidly new HPV testing approaches move from development into routine care. Recent FDA actions demonstrate that HPV assays can undergo changes involving indications, labeling, manufacturing processes, and specimen workflows. Maintaining consistent quality while incorporating new technologies can therefore create operational and compliance challenges. Healthcare providers must balance innovation with appropriate validation, staff training, laboratory quality assurance, and adherence to current cervical screening recommendations.

California – Innovation at the Forefront of HPV Screening

California provides a highly developed environment for HPV testing, supported by advanced healthcare networks, diagnostic laboratories, academic medical centers, and strong interest in preventive healthcare. The state’s diverse population creates demand for screening approaches that can accommodate different healthcare preferences and access patterns. Molecular testing, automated laboratory systems, and emerging self-collection models can help providers develop more flexible screening pathways. California is also closely connected with biotechnology and diagnostic innovation, creating opportunities for collaboration between healthcare institutions, technology companies, laboratories, and research organizations. HPV testing is increasingly positioned within broader cervical cancer prevention strategies, where primary HPV screening, cytology, genotyping, and appropriate follow-up work together. Continued adoption of convenient collection approaches and digital laboratory workflows can further strengthen the state’s testing ecosystem.

Texas – Expanding Screening Across a Vast Healthcare Landscape

Texas represents a substantial opportunity for HPV testing because of its extensive healthcare network and geographically diverse population. Hospitals, physician practices, laboratories, community health organizations, and specialized women’s-health providers all contribute to cervical cancer screening services. The state’s geographic scale makes accessibility particularly important, creating opportunities for testing approaches that reduce dependence on traditional in-clinic procedures. Self-collection and decentralized laboratory services can help expand screening pathways when appropriately implemented. Texas also has a growing diagnostic infrastructure capable of supporting molecular testing, automated specimen processing, and high-throughput laboratory operations. Continued emphasis on preventive healthcare and improved patient education can encourage greater engagement with HPV screening. Market development will increasingly depend on combining accurate molecular diagnostics with convenient access, effective follow-up, and coordinated healthcare delivery.

New York – Precision Diagnostics Meet Preventive Women’s Health

New York benefits from an extensive network of hospitals, academic medical centers, laboratories, specialist practices, and public-health organizations supporting HPV testing and cervical cancer prevention. The state’s sophisticated healthcare environment encourages adoption of molecular diagnostics, automated laboratory systems, and evidence-based screening pathways. Large healthcare institutions can also support research and evaluation of emerging HPV testing technologies, including expanded genotyping and self-collection approaches. Patient-centered testing is becoming increasingly important as providers seek ways to improve screening convenience while maintaining appropriate clinical follow-up. Molecular HPV testing can be integrated with cytology and other diagnostic assessments to support risk-based management. Continued collaboration among laboratories, healthcare providers, public-health organizations, and diagnostic manufacturers is expected to strengthen screening infrastructure and encourage wider adoption of innovative HPV testing solutions.

Florida – Accessible Screening for a Diverse Patient Population

Florida’s HPV testing market is supported by a broad healthcare ecosystem encompassing hospitals, outpatient clinics, laboratories, women’s-health practices, and community healthcare organizations. The state’s diverse patient population creates demand for screening strategies that are convenient, understandable, and accessible across different healthcare settings. Molecular HPV testing can provide an efficient approach to identifying high-risk infections and supporting cervical cancer prevention when incorporated into appropriate screening pathways. Self-collection represents another potential avenue for expanding access among eligible individuals who may prefer alternatives to conventional specimen collection. Florida’s healthcare providers are also increasingly adopting digital laboratory workflows and advanced diagnostic technologies to streamline patient services. Continued emphasis on preventive health, patient education, screening awareness, and timely follow-up can support broader utilization of HPV testing across the state.

United States HPV Testing for Cervical Cancer Screening Market

The United States HPV Testing for Cervical Cancer Screening Market is evolving as healthcare providers increasingly incorporate HPV molecular testing into preventive women’s-health programs. HPV testing can support primary screening, co-testing, and clinical triage, providing valuable information about high-risk viral infections associated with cervical cancer. The expansion of self-collected vaginal specimens is creating additional opportunities to make screening more convenient for eligible individuals. Laboratories are also adopting automated molecular platforms that streamline specimen preparation, amplification, detection, and reporting. Improved HPV genotyping can provide additional information for risk assessment and follow-up decisions. Partnerships between diagnostic manufacturers, laboratories, healthcare providers, and public-health organizations are supporting broader implementation of modern screening approaches. The market is therefore moving toward accessible, molecular-based, patient-centered cervical cancer prevention strategies.

United States HPV Testing Instruments Market

The United States HPV Testing Instruments Market is being shaped by demand for automated, reliable, and high-throughput molecular diagnostic platforms. Modern instruments support specimen preparation, nucleic-acid amplification, detection, data management, and standardized laboratory workflows. Compatibility with HPV assays is an important consideration for laboratories seeking to expand screening capacity while maintaining consistent testing performance. Platforms such as automated molecular systems can also facilitate integration with broader infectious-disease testing menus, improving laboratory utilization. Self-collection is creating another technology requirement, as laboratories need workflows capable of efficiently processing appropriately collected vaginal specimens. Manufacturers are increasingly emphasizing automation, workflow simplicity, connectivity, and scalable laboratory operations. As HPV screening moves toward molecular-first approaches in appropriate settings, demand for sophisticated instruments capable of supporting efficient specimen processing and reliable molecular analysis is expected to remain important.

United States Liquid-Based Cytology HPV Testing Market

The United States Liquid-Based Cytology HPV Testing Market combines molecular HPV detection with cytological evaluation using liquid-based specimen collection and preparation systems. This approach allows laboratories to use collected cervical specimens for HPV testing and cytology within coordinated screening workflows, depending on the clinical protocol. Liquid-based cytology can help improve specimen preparation and support standardized laboratory examination, while HPV molecular testing adds information about high-risk viral infection. The combined approach remains relevant for co-testing, abnormal cytology evaluation, and selected follow-up pathways. Advances in automated cytology preparation, digital pathology, molecular assays, and laboratory information systems are improving workflow integration. As healthcare providers increasingly adopt risk-based cervical screening strategies, liquid-based specimen systems can continue serving as an important bridge between conventional cytology services and modern molecular HPV diagnostics.

United States Hospitals & Clinics HPV Testing Market

The United States Hospitals & Clinics HPV Testing Market is supported by the integration of HPV diagnostics into preventive healthcare, gynecology, oncology, and primary-care services. Hospitals and clinics commonly coordinate specimen collection, laboratory testing, result interpretation, patient counseling, and follow-up within broader cervical cancer screening pathways. The availability of molecular HPV assays and self-collection options is giving providers additional flexibility in how eligible patients access screening. Larger healthcare systems can also integrate HPV testing with electronic health records, laboratory information systems, cytology services, and referral networks. Clinics increasingly value testing approaches that simplify workflows while maintaining appropriate quality and clinical oversight. Continued investment in molecular diagnostics, patient education, laboratory connectivity, and coordinated follow-up can strengthen HPV testing utilization across hospitals, outpatient centers, women’s-health practices, and community-based healthcare settings.

Market Segmentations

Application

• Cervical Cancer Screening
• Vaginal Cancer Screening

Product

• Consumables
• Instruments
• Services

Distribution Channels

• Polymerase chain reaction (PCR)
• Liquid-based cytology
• Immunodiagnostics
• Hybrid Capture
• Others

End Use

• Hospitals & Clinics
• Laboratories
• Others

States

• California
• Texas
• New York
• Florida
• Illinois
• Pennsylvania
• Ohio
• Georgia
• New Jersey
• Washington
• North Carolina
• Massachusetts
• Virginia
• Michigan
• Maryland
• Colorado
• Tennessee
• Indiana
• Arizona
• Minnesota
• Wisconsin
• Missouri
• Connecticut
• South Carolina
• Oregon
• Louisiana
• Alabama
• Kentucky
• Rest of United States

All Key Players have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

• Abbott Laboratories
• BioMerieux SA
• Bio-Rad Laboratories, Inc.
• Epigenomics AG
• Siemens Healthineers AG
• Hologic Inc
• Qiagen NV
• F. Hoffmann-La Roche Ltd

Report Details: